Anti-interleukin-17A antibody, pharmaceutical composition thereof and use thereof
AssigneeAkeso Biopharma, Inc.
InventorsBaiyong Li, Yu Xia, Zhongmin Maxwell Wang, Peng Zhang
Life of this patent
Estimating the term…
Loading patent…
AssigneeAkeso Biopharma, Inc.
InventorsBaiyong Li, Yu Xia, Zhongmin Maxwell Wang, Peng Zhang
Estimating the term…
The present invention relates to the fields of treating autoimmune diseases and molecular immunology, and specifically, to an anti-IL-17A antibody, a pharmaceutical composition thereof, and use thereof. The present invention relates to a monoclonal antibody or an antigen binding fragment thereof, wherein a heavy chain variable region of the monoclonal antibody comprises: HCDR1-HCDR3 with amino acid sequences set forth in SEQ ID NOs: 31-33 respectively, or HCDR1-HCDR3 with amino acid sequences set forth in SEQ ID NOs: 37-39 respectively, and a light chain variable region of the monoclonal antibody comprises: LCDR1-LCDR3 with amino acid sequences set forth in SEQ ID NOs: 34-36 respectively, or LCDR1-LCDR3 with amino acid sequences set forth in SEQ ID NOs: 40-42 respectively. Monoclonal antibodies of the present invention can specifically antagonize the binding of IL-17A to a ligand and inhibit activation of fibroblasts by IL-17A.
An anti-interleukin-17A (anti-IL-17A) monoclonal antibody or an antigen-binding fragment thereof comprising:
Dependencies are inferred from the claim text.